BIOPOR Bioporto A/S

BioPorto receives communication from FDA regarding The NGAL Testâ„¢

BioPorto receives communication from FDA regarding The NGAL Test™

October 3, 2018

Announcement no. 17

BioPorto receives communication from FDA regarding The NGAL Test™

BioPorto A/S (“BioPorto”) announces today that the company has received communication from the U.S. Food and Drug Administration (“FDA”) regarding the application for regulatory clearance of The NGAL Test™ for risk use with acute kidney injury in the U.S.

The communication states that additional data will be required to support the AKI rule-out claim in order to continue the application process. BioPorto will now enter into a dialogue with FDA to further clarify these issues. Based on the foregoing, Management’s expectation as to the timing of FDA’s decision regarding clearance of The NGAL Test ™ is therefore postponed to mid-2019. 

BioPorto will continue its evaluation of the matters addressed in the communication from the FDA and will announce any new material decision or news regarding the NGAL approval process.

The content of this announcement does not alter BioPorto’s financial guidance for 2018 as most recently expressed in the interim report for the second quarter of 2018.

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. BioPorto has its headquarters in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange.

Attachment

EN
03/10/2018

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto A/S udnævner CFO

BioPorto A/S udnævner CFO 9. februar, 2026Meddelelse nr. 2 BioPorto A/S udnævner CFO BioPorto A/S (BioPorto) (CPH:BIOPOR) annoncerede i dag udnævnelsen af Klaus Juhl Wulff som ny Executive Vice President (EVP) og Chief Financial Officer (CFO) samt medlem af Executive Management-teamet senest pr. 1. maj 2026. Klaus Juhl Wulff er en højt kvalificeret leder med mere end 20 års erfaring inden for finans, drift, M&A og kapitalmarkeder. Han kommer til BioPorto fra AquaPorin A/S, hvor han var CFO fra 2022. Før dette har Klaus Juhl Wulff fungeret som CFO i forskellige virksomheder. Klaus Juhl W...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto A/S Appoints Chief Financial Officer

BioPorto A/S Appoints Chief Financial Officer February 9, 2026Announcement no. 2 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive Management team as of latest May 1st, 2026. Klaus Juhl Wulff is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from AquaPorin A/S, where he served as CFO from 2022. Prior to this, Klaus Juhl...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, fin...

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering  5. februar 2026Meddelelse nr. 1 BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering                                                                         KØBENHAVN, DANMARK, 5. februar, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller Selskabet) (CPH:BIOPOR), annoncerede i dag foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopd...

February 5, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financ...

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update  February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update                                                                         COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a business update.                       ...

February 5, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Ændringer i selskabets Direktion

Ændringer i selskabets Direktion 11. december 2025 Meddelelse nr. 29 Ændringer i selskabets Direktion KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. december 2025 (GLOBE NEWSWIRE) – BioPorto A/S ("BioPorto") (CPH:BIOPOR) meddelte i dag, at Niels Høy Nielsen har opsagt sin stilling som CFO for BioPorto for at tiltræde en CFO-stilling i et andet selskab. "Jeg har værdsat det tætte samarbejde med Niels i de sidste par måneder, siden jeg tiltrådte min stilling i BioPorto. Niels har ydet vigtige bidrag til virksomheden og jeg ønsker ham alt det bedste i hans fremtidige stilling," sagde Carsten B...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch